Corcept Therapeutics Inc [CORT] stock prices are down -0.56% to $75.12 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CORT shares have lost -0.49% over the last week, with a monthly amount drifted -4.54%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with an Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.
The stock price of Corcept Therapeutics Inc [CORT] has been fluctuating between $49.00 and $117.33 over the past year. Currently, Wall Street analysts expect the stock to reach $140 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $75.12 at the most recent close of the market. An investor can expect a potential return of 86.37% based on the average CORT price forecast.
Analyzing the CORT fundamentals
The Corcept Therapeutics Inc [NASDAQ:CORT] reported sales of 741.17M for trailing twelve months, representing a surge of 13.75%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.16 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 74.28 points at the first support level, and at 73.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 76.38, and for the 2nd resistance point, it is at 77.64.
Ratios To Look Out For
It’s worth pointing out that Corcept Therapeutics Inc [NASDAQ:CORT]’s Current Ratio is 3.14. Also, the Quick Ratio is 3.07, while the Cash Ratio stands at 0.73. Considering the valuation of this stock, the price to sales ratio is 10.66, the price to book ratio is 12.50 and price to earnings (TTM) ratio is 85.83.
Transactions by insiders
Recent insider trading involved Guyer William, Chief Development Officer, that happened on Nov 05 ’25 when 20000.0 shares were sold. Lyon Joseph Douglas completed a deal on Nov 03 ’25 to sell 5000.0 shares. Meanwhile, Chief Executive Officer BELANOFF JOSEPH K sold 28782.0 shares on Nov 05 ’25.
